-+ 0.00%
-+ 0.00%
-+ 0.00%
According to Zhitong Finance App News, Xinbang Pharmaceutical (002390.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 2,467 billion yuan, down 13.29% from the same period of the previous year; net profit attributable to shareholders of listed companies was 99.5863 million yuan, down 7.1% from the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 76.361 million yuan, down 28.13% from the same period last year; basic earnings per share were 0.0525 yuan. The company plans to distribute a cash dividend of 0.3 yuan (tax included) for every 10 shares to all shareholders.
Share
Listen to the news
According to Zhitong Finance App News, Xinbang Pharmaceutical (002390.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 2,467 billion yuan, down 13.29% from the same period of the previous year; net profit attributable to shareholders of listed companies was 99.5863 million yuan, down 7.1% from the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 76.361 million yuan, down 28.13% from the same period last year; basic earnings per share were 0.0525 yuan. The company plans to distribute a cash dividend of 0.3 yuan (tax included) for every 10 shares to all shareholders.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending